SK282172B6 - D-tartarát (-)-cis-6(s)-fenyl-5(r)-[4-(2-pyrolidin-1- yletoxy)fenyl]-5,6,7,8-tetrahydronaftalen-2-olu, spôsob jeho výroby a farmaceutické prostriedky na jeho báze - Google Patents

D-tartarát (-)-cis-6(s)-fenyl-5(r)-[4-(2-pyrolidin-1- yletoxy)fenyl]-5,6,7,8-tetrahydronaftalen-2-olu, spôsob jeho výroby a farmaceutické prostriedky na jeho báze Download PDF

Info

Publication number: SK282172B6
Authority: SK; Slovakia
Prior art keywords: phenyl; cis; pyrrolidin; tartrate; solution
Prior art date: 1995-11-02

Application number

SK542-98A

Other languages

English (en)

Slovak (sk)

Other versions

SK54298A3 (en

Inventor

Charles K. Chiu

Morgan Meltz

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-02

Filing date

1996-10-04

Publication date

2001-11-06

1996-10-04 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

1999-07-12 Publication of SK54298A3 publication Critical patent/SK54298A3/sk

2001-11-06 Publication of SK282172B6 publication Critical patent/SK282172B6/sk

Links

238000000034 method Methods 0.000 title claims abstract description 14
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title claims abstract description 10
238000002360 preparation method Methods 0.000 title claims description 4
FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 54
-1 2-pyrrolidin-1-ylethoxy Chemical group 0.000 claims abstract description 13
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 6
229960001270 d- tartaric acid Drugs 0.000 claims abstract description 6
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
230000008569 process Effects 0.000 claims abstract description 6
238000001816 cooling Methods 0.000 claims abstract description 5
238000009835 boiling Methods 0.000 claims abstract description 4
241000124008 Mammalia Species 0.000 claims description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 7
208000008589 Obesity Diseases 0.000 claims description 5
235000020824 obesity Nutrition 0.000 claims description 5
206010006187 Breast cancer Diseases 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 4
208000024172 Cardiovascular disease Diseases 0.000 claims description 4
201000009273 Endometriosis Diseases 0.000 claims description 4
208000001132 Osteoporosis Diseases 0.000 claims description 4
208000017497 prostate disease Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
208000031226 Hyperlipidaemia Diseases 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 32
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract description 3
238000004519 manufacturing process Methods 0.000 abstract description 2
239000000243 solution Substances 0.000 description 38
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
241001465754 Metazoa Species 0.000 description 11
229910052500 inorganic mineral Inorganic materials 0.000 description 11
235000010755 mineral Nutrition 0.000 description 11
239000011707 mineral Substances 0.000 description 11
239000000203 mixture Substances 0.000 description 11
239000007787 solid Substances 0.000 description 11
230000002265 prevention Effects 0.000 description 10
239000000047 product Substances 0.000 description 10
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
150000003839 salts Chemical class 0.000 description 8
210000000988 bone and bone Anatomy 0.000 description 7
229930182833 estradiol Natural products 0.000 description 7
229960005309 estradiol Drugs 0.000 description 7
229940011871 estrogen Drugs 0.000 description 7
239000000262 estrogen Substances 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000010410 layer Substances 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
239000000556 agonist Substances 0.000 description 5
230000027455 binding Effects 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
210000002307 prostate Anatomy 0.000 description 5
NAPIZYZVKMASNP-PXJZQJOASA-N 1-[2-[4-[(1r,2s)-6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenoxy]ethyl]pyrrolidine Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 NAPIZYZVKMASNP-PXJZQJOASA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
229910052943 magnesium sulfate Inorganic materials 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
238000009806 oophorectomy Methods 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
239000002287 radioligand Substances 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
238000003756 stirring Methods 0.000 description 4
HJOOGTROABIIIU-UHFFFAOYSA-N 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine;hydrochloride Chemical compound Cl.C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 HJOOGTROABIIIU-UHFFFAOYSA-N 0.000 description 3
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
208000035150 Hypercholesterolemia Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000002585 base Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
230000037182 bone density Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
238000010992 reflux Methods 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000012453 sprague-dawley rat model Methods 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
MNALUTYMBUBKNX-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(OC)=CC=C21 MNALUTYMBUBKNX-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
206010030247 Oestrogen deficiency Diseases 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
241000700159 Rattus Species 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000037118 bone strength Effects 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229960001701 chloroform Drugs 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
230000002357 endometrial effect Effects 0.000 description 2
210000004696 endometrium Anatomy 0.000 description 2
102000015694 estrogen receptors Human genes 0.000 description 2
108010038795 estrogen receptors Proteins 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000003446 ligand Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
239000008188 pellet Substances 0.000 description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000013223 sprague-dawley female rat Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229960003604 testosterone Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
238000003828 vacuum filtration Methods 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
WLYGYGVONLWBGO-XMMPIXPASA-N (5R)-1-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1(=CC=CC=C1)C1=C(C=CC=2[C@H](CCCC1=2)C1=CC=C(C=C1)OCCN1CCCC1)O WLYGYGVONLWBGO-XMMPIXPASA-N 0.000 description 1
JEHUZVBIUCAMRZ-UHFFFAOYSA-N 1,1'-binaphthyl-2,2'-diyl hydrogenphosphate Chemical class O1P(O)(=O)OC2=CC=C(C=CC=C3)C3=C2C2=C1C=CC1=CC=CC=C21 JEHUZVBIUCAMRZ-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
SRSIBTJGQWSANT-UHFFFAOYSA-N 1-[2-[4-(2-bromo-6-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine Chemical compound BrC=1CCC2=CC(OC)=CC=C2C=1C(C=C1)=CC=C1OCCN1CCCC1 SRSIBTJGQWSANT-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000008899 Habitual abortion Diseases 0.000 description 1
206010020112 Hirsutism Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010051459 Imminent abortion Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027514 Metrorrhagia Diseases 0.000 description 1
JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
YDWKSSWZGXRQET-UHFFFAOYSA-N Pyrrolidine, 1-[2-(4-bromophenoxy)ethyl]- Chemical compound C1=CC(Br)=CC=C1OCCN1CCCC1 YDWKSSWZGXRQET-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
235000012501 ammonium carbonate Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
239000001354 calcium citrate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000062 effect on obesity Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
230000006408 female gonad development Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
239000001341 hydroxy propyl starch Substances 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000006651 lactation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
VDCLSGXZVUDARN-UHFFFAOYSA-N molecular bromine;pyridine;hydrobromide Chemical compound Br.BrBr.C1=CC=NC=C1 VDCLSGXZVUDARN-UHFFFAOYSA-N 0.000 description 1
210000000754 myometrium Anatomy 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
230000010076 replication Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
229940001607 sodium bisulfite Drugs 0.000 description 1
229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003356 suture material Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
235000013337 tricalcium citrate Nutrition 0.000 description 1
RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK542-98A 1995-11-02 1996-10-04 D-tartarát (-)-cis-6(s)-fenyl-5(r)-[4-(2-pyrolidin-1- yletoxy)fenyl]-5,6,7,8-tetrahydronaftalen-2-olu, spôsob jeho výroby a farmaceutické prostriedky na jeho báze SK282172B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US612595P	1995-11-02	1995-11-02
PCT/IB1996/001049 WO1997016434A1 (en)	1995-11-02	1996-10-04	(-) cis-6(s)-phenyl-5(r)[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate

Publications (2)

Publication Number	Publication Date
SK54298A3 SK54298A3 (en)	1999-07-12
SK282172B6 true SK282172B6 (sk)	2001-11-06

Family

ID=21719433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK542-98A SK282172B6 (sk)	1995-11-02	1996-10-04	D-tartarát (-)-cis-6(s)-fenyl-5(r)-[4-(2-pyrolidin-1- yletoxy)fenyl]-5,6,7,8-tetrahydronaftalen-2-olu, spôsob jeho výroby a farmaceutické prostriedky na jeho báze

Country Status (43)

Country	Link
US (1)	US5948809A (cs)
EP (1)	EP0876359B1 (cs)
JP (1)	JP3088020B2 (cs)
KR (1)	KR19990067280A (cs)
CN (1)	CN1067065C (cs)
AP (1)	AP713A (cs)
AR (1)	AR004078A1 (cs)
AT (1)	ATE248827T1 (cs)
AU (1)	AU708841B2 (cs)
BG (1)	BG63943B1 (cs)
BR (1)	BR9611436A (cs)
CA (1)	CA2236673C (cs)
CO (1)	CO4770967A1 (cs)
CZ (1)	CZ287341B6 (cs)
DE (1)	DE69629837T2 (cs)
DK (1)	DK0876359T3 (cs)
DZ (1)	DZ2114A1 (cs)
EG (1)	EG21095A (cs)
ES (1)	ES2203713T3 (cs)
GT (1)	GT199600085A (cs)
HR (1)	HRP960503B1 (cs)
HU (1)	HU227521B1 (cs)
IL (1)	IL124027A (cs)
IS (1)	IS1855B (cs)
MA (1)	MA23998A1 (cs)
NO (1)	NO310358B1 (cs)
NZ (1)	NZ318498A (cs)
OA (1)	OA11009A (cs)
PE (1)	PE17698A1 (cs)
PL (1)	PL188633B1 (cs)
PT (1)	PT876359E (cs)
RO (1)	RO119829B1 (cs)
RU (1)	RU2162465C2 (cs)
SI (1)	SI0876359T1 (cs)
SK (1)	SK282172B6 (cs)
TN (1)	TNSN96134A1 (cs)
TR (1)	TR199800783T2 (cs)
TW (2)	TW518327B (cs)
UA (1)	UA51676C2 (cs)
UY (1)	UY24362A1 (cs)
WO (1)	WO1997016434A1 (cs)
YU (1)	YU49123B (cs)
ZA (1)	ZA969212B (cs)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL120266A (en) *	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9703109D0 (en) *	1997-02-14	1997-04-02	Smith & Nephew	Compositions
JP2002518328A (ja) *	1998-06-16	2002-06-25	ファイザー・プロダクツ・インク	筋骨格虚弱の治療用の（選択的）エストロゲン受容体モジュレーター（ｓｅｒｍ）および成長ホルモン分泌促進薬（ｇｈｓ）の治療的組合せ
HN1999000097A (es) *	1998-06-16	1999-11-03	Pfizer Prod Inc	Terapia de combinacion para la fragilidad muscoloesqueletica
ES2220005T3 (es) *	1998-06-16	2004-12-01	Pfizer Products Inc.	Combinaciones terapeuticas que comprenden un modulador selectivo del receptor de estrogeno y prostaglandina e2.
YU26700A (sh) *	1999-05-24	2002-06-19	Pfizer Products Inc.	Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
CO5271697A1 (es)	2000-01-12	2003-04-30	Pfizer Prod Inc	Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271696A1 (es) *	2000-01-12	2003-04-30	Pfizer Prod Inc	Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5251465A1 (es) *	2000-01-26	2003-02-28	Pfizer Prod Inc	Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
AP2002002641A0 (en)	2000-04-07	2002-12-31	Pfizer Prod Inc	Estrogen agonist metabolites.
US20020013327A1 (en) *	2000-04-18	2002-01-31	Lee Andrew G.	Compositions and methods for treating female sexual dysfunction
ATE346159T1 (de)	2000-05-08	2006-12-15	Pfizer Prod Inc	Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors
IL145838A (en) *	2000-10-16	2008-11-03	Pfizer Prod Inc	Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
TWI303990B (en)	2000-10-17	2008-12-11	Pfizer Prod Inc	New use of estrogen agonists/antagonists for improving vascular health
AU781168B2 (en) *	2001-01-26	2005-05-12	Pfizer Products Inc.	Method of treating certain cancers using an estrogen agonist/antagonist
AU2756602A (en) *	2001-04-25	2002-10-31	Pfizer Products Inc.	Methods and kits for treating depression or preventing deterioration of cognitive function
GEP20053654B (en)	2001-05-01	2005-11-10	Pfizer Prod Inc	Method For Manufacturing Low Dose Pharmaceutical Composition Having Uniform Drug Distribution
EP1411922A1 (en) *	2001-07-31	2004-04-28	Pfizer Products Inc.	Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
RU2317104C2 (ru) *	2001-09-24	2008-02-20	Импиэриэл Инноувейшнс Лимитид	Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
RS80604A (sr) *	2002-03-28	2007-02-05	Pfizer Products Inc.,	Prečišćen lazofoksifen i postupci prečišćavanja lazofoksifena rekristalizacijom
PA8576201A1 (es) *	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7444197B2 (en)	2004-05-06	2008-10-28	Smp Logic Systems Llc	Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US7799273B2 (en)	2004-05-06	2010-09-21	Smp Logic Systems Llc	Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
JP2008503561A (ja) *	2004-06-21	2008-02-07	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	骨芽細胞機能を刺激するためのｐｙｋ２阻害薬
BRPI0512245A (pt) *	2004-06-30	2008-02-19	Lilly Co Eli	composto, composição farmacêutica, e, uso do composto
ATE482940T1 (de)	2005-06-22	2010-10-15	Pfizer Prod Inc	Stereoselektives hydrierverfahren zur herstellung von cis-6-phenyl-5-ä4-(2-pyrrolidin-1-yl-ethoxy)- phenylü-2-methoxy-5,6,7,8-tetrahydronaphthalin- hydrochlorid
CZ2007373A3 (cs) *	2007-05-29	2008-12-10	Zentiva, A. S	Zpusob prípravy lasofoxifenu
EP2424839A4 (en)	2009-04-29	2012-10-17	Glenmark Generics Ltd	PROCESS FOR THE PREPARATION OF LASOFOXIFEN TARTRATE
KR101149529B1 (ko)	2009-09-11	2012-05-25	한국화학연구원	인덴온 유도체 및 이를 포함하는 약학적 조성물
CN103113323B (zh) *	2013-02-05	2015-11-11	南京华威医药科技开发有限公司	酒石酸拉索昔芬中间体的制备方法
US20180098963A1 (en)	2016-10-11	2018-04-12	Duke University	Lasofoxifene treatment of breast cancer
CN117771239A (zh)	2018-04-10	2024-03-29	杜克大学	乳腺癌的拉索昔芬治疗
KR20220115062A (ko)	2021-02-09	2022-08-17	(주)오스티오뉴로젠	크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물
GB202116903D0 (en)	2021-11-18	2022-01-05	Sermonix Pharmaceuticals Inc	Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2025043004A1 (en)	2023-08-21	2025-02-27	Duke University	Treatment of solid cancer with lasofoxifene

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3274213A (en) *	1961-09-05	1966-09-20	Upjohn Co	Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) *	1962-09-10	1966-02-08	Ciba Geigy Corp	Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) *	1964-01-23	1970-07-28	Ciba Geigy Corp	Phenol substituted tetrahydronaphthalenes useful as estrogenics
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

1996
- 1996-04-10 UA UA98042214A patent/UA51676C2/uk unknown
- 1996-09-30 TW TW085111903A patent/TW518327B/zh not_active IP Right Cessation
- 1996-09-30 TW TW091125091A patent/TW581766B/zh not_active IP Right Cessation
- 1996-10-04 AU AU69984/96A patent/AU708841B2/en not_active Expired
- 1996-10-04 DE DE69629837T patent/DE69629837T2/de not_active Expired - Lifetime
- 1996-10-04 IL IL12402796A patent/IL124027A/en not_active IP Right Cessation
- 1996-10-04 NZ NZ318498A patent/NZ318498A/xx not_active IP Right Cessation
- 1996-10-04 KR KR1019980703251A patent/KR19990067280A/ko not_active Ceased
- 1996-10-04 ES ES96931206T patent/ES2203713T3/es not_active Expired - Lifetime
- 1996-10-04 PT PT96931206T patent/PT876359E/pt unknown
- 1996-10-04 CN CN96198048A patent/CN1067065C/zh not_active Expired - Lifetime
- 1996-10-04 CA CA002236673A patent/CA2236673C/en not_active Expired - Lifetime
- 1996-10-04 WO PCT/IB1996/001049 patent/WO1997016434A1/en not_active Ceased
- 1996-10-04 JP JP09517180A patent/JP3088020B2/ja not_active Expired - Lifetime
- 1996-10-04 BR BR9611436A patent/BR9611436A/pt not_active Application Discontinuation
- 1996-10-04 RU RU98110128/04A patent/RU2162465C2/ru active
- 1996-10-04 SK SK542-98A patent/SK282172B6/sk not_active IP Right Cessation
- 1996-10-04 TR TR1998/00783T patent/TR199800783T2/xx unknown
- 1996-10-04 CZ CZ19981320A patent/CZ287341B6/cs not_active IP Right Cessation
- 1996-10-04 HU HU9900087A patent/HU227521B1/hu unknown
- 1996-10-04 US US09/065,094 patent/US5948809A/en not_active Expired - Lifetime
- 1996-10-04 SI SI9630635T patent/SI0876359T1/xx unknown
- 1996-10-04 RO RO98-00926A patent/RO119829B1/ro unknown
- 1996-10-04 EP EP96931206A patent/EP0876359B1/en not_active Expired - Lifetime
- 1996-10-04 DK DK96931206T patent/DK0876359T3/da active
- 1996-10-04 AT AT96931206T patent/ATE248827T1/de active
- 1996-10-04 PL PL96326498A patent/PL188633B1/pl unknown
- 1996-10-11 GT GT199600085A patent/GT199600085A/es unknown
- 1996-10-23 AR ARP960104862A patent/AR004078A1/es active IP Right Grant
- 1996-10-29 HR HR960503A patent/HRP960503B1/xx not_active IP Right Cessation
- 1996-10-30 DZ DZ960158A patent/DZ2114A1/fr active
- 1996-10-30 PE PE1996000753A patent/PE17698A1/es not_active Application Discontinuation
- 1996-10-30 TN TNTNSN96134A patent/TNSN96134A1/fr unknown
- 1996-10-30 MA MA24381A patent/MA23998A1/fr unknown
- 1996-10-30 EG EG95996A patent/EG21095A/xx active
- 1996-10-31 AP APAP/P/1996/000880A patent/AP713A/en active
- 1996-11-01 YU YU57896A patent/YU49123B/sh unknown
- 1996-11-01 CO CO96057925A patent/CO4770967A1/es unknown
- 1996-11-01 ZA ZA9609212A patent/ZA969212B/xx unknown
- 1996-11-04 UY UY24362A patent/UY24362A1/es unknown
1998
- 1998-04-16 IS IS4718A patent/IS1855B/is unknown
- 1998-04-29 OA OA9800046A patent/OA11009A/en unknown
- 1998-04-30 NO NO19981962A patent/NO310358B1/no not_active IP Right Cessation
- 1998-05-21 BG BG102474A patent/BG63943B1/bg unknown

Also Published As

Publication number	Publication date
HUP9900087A2 (hu)	1999-05-28
IS4718A (is)	1998-04-16
AU708841B2 (en)	1999-08-12
CN1201458A (zh)	1998-12-09
EP0876359B1 (en)	2003-09-03
DE69629837T2 (de)	2004-05-06
AP713A (en)	1998-12-28
DK0876359T3 (da)	2003-11-24
NO981962L (no)	1998-04-30
HRP960503A2 (en)	1998-04-30
CA2236673C (en)	2002-03-19
NO310358B1 (no)	2001-06-25
IL124027A (en)	2001-10-31
EG21095A (en)	2000-10-31
EP0876359A1 (en)	1998-11-11
GT199600085A (es)	1998-04-04
HU227521B1 (en)	2011-07-28
RU2162465C2 (ru)	2001-01-27
NZ318498A (en)	1999-06-29
CA2236673A1 (en)	1997-05-09
SI0876359T1 (en)	2003-12-31
OA11009A (en)	2003-03-03
TNSN96134A1 (fr)	1998-12-31
RO119829B1 (ro)	2005-04-29
UA51676C2 (uk)	2002-12-16
PE17698A1 (es)	1998-04-18
CN1067065C (zh)	2001-06-13
ES2203713T3 (es)	2004-04-16
IS1855B (is)	2003-02-21
HRP960503B1 (en)	2001-12-31
WO1997016434A1 (en)	1997-05-09
ATE248827T1 (de)	2003-09-15
BR9611436A (pt)	1999-03-23
PL326498A1 (en)	1998-09-28
AP9600880A0 (en)	1997-01-31
YU57896A (sh)	1998-12-23
CZ287341B6 (en)	2000-10-11
PL188633B1 (pl)	2005-03-31
AU6998496A (en)	1997-05-22
YU49123B (sh)	2004-03-12
BG102474A (en)	1999-06-30
HUP9900087A3 (en)	1999-11-29
MX9803544A (es)	1998-09-30
SK54298A3 (en)	1999-07-12
ZA969212B (en)	1998-05-04
JP3088020B2 (ja)	2000-09-18
TR199800783T2 (xx)	1998-08-21
CO4770967A1 (es)	1999-04-30
UY24362A1 (es)	1997-04-24
PT876359E (pt)	2003-12-31
TW581766B (en)	2004-04-01
KR19990067280A (ko)	1999-08-16
DE69629837D1 (de)	2003-10-09
JPH11502866A (ja)	1999-03-09
CZ132098A3 (cs)	1999-03-17
AR004078A1 (es)	1998-09-30
BG63943B1 (bg)	2003-07-31
DZ2114A1 (fr)	2002-07-22
NO981962D0 (no)	1998-04-30
TW518327B (en)	2003-01-21
US5948809A (en)	1999-09-07
MA23998A1 (fr)	1997-07-01

Legal Events

Date	Code	Title	Description
2013-07-02	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20121004

Publication	Publication Date	Title
SK282172B6 (sk)	2001-11-06	D-tartarát (-)-cis-6(s)-fenyl-5(r)-[4-(2-pyrolidin-1- yletoxy)fenyl]-5,6,7,8-tetrahydronaftalen-2-olu, spôsob jeho výroby a farmaceutické prostriedky na jeho báze
US6153622A (en)	2000-11-28	Estrogen agonists/antagonists
JP2000080038A (ja)	2000-03-21	エストロゲンアゴニスト及びアンタゴニスト
MXPA98003544A (en)	1998-11-16	D-tartrate (-) - cis-6 (s) -fenil-5 (r) - [4- (2-pyrrolidin-1-iletoxy) phenyl] -5,6,7,8-tetrahydronatalen-2
MXPA97005145A (en)	1998-07-03	Agonists / stroke antagonists